Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 3:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 309 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Age-Related Macular Degeneration
Interventions
Palomid 529
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Completed No phase listed Observational Accepts healthy volunteers

Study Evaluating Retinal Health Monitoring System Visual Acuity Module.

NCT04169802
Conditions
Age Related Macular Degeneration
Interventions
Retinal Health Monitoring System Visual Acuity Module, Sloan letter, logarithmic near visual acuity chart (Reference Chart)
Diagnostic Test
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Neovascular Age-related Macular Degeneration
Interventions
SAR402663, Diluent
Biological · Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years to 90 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 14 more
Conditions
Neovascular Age-related Macular Degeneration
Interventions
CLS-AX, Anti-VEGF
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
50 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Bakersfield, California • Mountain View, California + 8 more
Conditions
Macular Degeneration
Interventions
Verteporfin Therapy/ Drug: Bevacizumab
Device
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
New York, New York
Conditions
Age Related Macular Degeneration
Interventions
Subretinally injected RetinoStat
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Prism Vision Group
Other
Eligibility
65 Years to 90 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Edison, New Jersey
Conditions
Age-Related Macular Degeneration
Interventions
E10030 plus Lucentis, Lucentis
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years to 100 Years
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
West Columbia, South Carolina
Conditions
Macula; Degeneration, Retina
Interventions
carbidopa-levodopa 25-100 mg
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Age-related Macular Degeneration
Interventions
RetnaGene AMD LDT
Device
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Conditions
Dry Macular Degeneration
Interventions
SS-OCT imaging
Device
Lead sponsor
Boston Image Reading Center
Industry
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Conditions
Age-Related Macular Degeneration
Interventions
Palomid 529
Drug
Lead sponsor
Paloma Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Neovascular Age-related Macular Degeneration
Interventions
AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose
Drug
Lead sponsor
AsclepiX Therapeutics, Inc.
Industry
Eligibility
50 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Springfield, Massachusetts • St Louis, Missouri • Asheville, North Carolina + 1 more
Conditions
Age-Related Macular Degeneration, Macular Degeneration
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Cherry Hill, New Jersey • Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Placebo, LFG316
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio
Conditions
Wet Macular Degeneration
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more
Conditions
Neovascular Age-related Macular Degeneration
Interventions
brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more
Conditions
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
61
States / cities
Arcadia, California • Bakersfield, California • Beverly Hills, California + 57 more
Conditions
Age-Related Macular Degeneration
Interventions
combination ranibizumab + bromfenac, ranibizumab injection alone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Completed Not applicable Interventional Accepts healthy volunteers

NVAMD Satellite Study

NCT02251366
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Physician-guided diagnostic
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more
Conditions
Geographic Atrophy of the Macula
Interventions
GAL-101, Placebo
Drug
Lead sponsor
Galimedix Therapeutics Inc
Industry
Eligibility
55 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions
Faricimab, Port Delivery System with Ranibizumab
Drug · Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more